Summary & Overview
HCPCS Level II J9172: Docetaxel (Docivyx) Injection, 1 mg
HCPCS Level II code J9172 denotes a 1 mg unit of docetaxel (branded Docivyx) for intravenous chemotherapy administration. This oncology drug code is used across outpatient infusion sites and physician offices to capture billed units of a widely used antineoplastic agent. Nationally, accurate coding for high-cost oncology drugs like docetaxel matters for clinical documentation, payer coverage determinations, and budgetary planning at both provider and payer levels.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coverage considerations, common billing modifiers, and clinical context for docetaxel use. The publication reviews unitization and typical sites of service, summarizes payer coverage patterns, and highlights areas where billing clarity is important for claims processing and reimbursement integrity.
The content provides benchmarks for billed units and utilization trends, discusses recent policy updates that affect oncology infusion billing, and explains clinical indications that commonly accompany docetaxel administration. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J9172 represents Injection, docetaxel (docivyx), 1 mg. This code is used to bill for parenteral administration of the chemotherapy agent docetaxel in its branded formulation Docivyx, dosed per milligram.
-
Service type: Intravenous chemotherapy infusion (antineoplastic agent)
-
Typical site of service: Hospital outpatient infusion centers, physician offices, and ambulatory infusion clinics where intravenous chemotherapy is administered
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a solid tumor (for example, metastatic breast cancer, non-small cell lung cancer, prostate cancer, or gastric adenocarcinoma) scheduled to receive systemic chemotherapy with docetaxel (J9172, 1 mg per unit). The patient presents to an outpatient oncology infusion center or hospital outpatient infusion clinic for administration. Pre-visit workflow includes verification of diagnosis and staging, review of current laboratory results (notably absolute neutrophil count and liver function tests), confirmation of chemotherapy order and dose calculation based on body surface area, and consent for chemotherapy with discussion of expected adverse effects. On arrival, nursing performs medication reconciliation, confirms identity, assesses intravenous access (peripheral IV or implanted port), and reviews premedication orders (commonly corticosteroid and antihistamine to reduce hypersensitivity and fluid retention). The pharmacy compounds the appropriate docetaxel dose using sterile technique and prepares labeled infusion tubing; J9172 units are billed per milligram administered. During infusion, nursing monitors vital signs and infusion tolerance; interventions for infusion reactions or extravasation are documented. Post-infusion, the patient is observed per protocol, given oral and written aftercare instructions, and the oncology team documents administered dose, lot numbers (or discarded amount when modifier JW applies), and any applicable modifier (for example, QK for qualified non-physician oncologist administration in certain payer arrangements). Typical sites of service are outpatient infusion centers, hospital outpatient departments, and physician office infusion suites that bill outpatient chemotherapy services.